Dendritic cell vaccination in combination with TLR-7 agonist, imiquimod, following radio-chemotherapy for newly diagnosed glioblastoma

• DOI: 10.1200/jco.2007.25.18_suppl.2021
• Publication Date: 2020-03-06T20:48:56Z
• Authors: L. M. Liau; R. M. Prins; S. K. Odesa; M. Y. Yang; M. S. Lin; H. Khan-Farooqi; H. Soto; A. Lai; M. Bosch; A. Boynton; T. F. Cloughesy
• Keywords: Imiquimod; Clinical endpoint

2021 Background: Standard therapy for glioblastoma, which includes surgery followed by radiation and concurrent chemotherapy, creates a low tumor burden environment that could be ideal immunotherapeutic approaches. We conducted Phase I study to assess the safety immunologic responses of lysate-pulsed dendritic cell (DC) plus topical imiquimod, in combination with standard radio-chemotherapy. Methods: Thirteen patients newly diagnosed glioblastoma were immunized using autologous DC. Each patient initially received 3 immunizations at 2-week intervals, following completion 6-week course radio- chemotherapy. Four 1 million DC, 4 5 million, 10 DC per immunization. Patients without progression subsequently booster vaccinations combined administration TLR-7 agonist imiquimod. Immunologic antigens monitored HLA-restricted tetramer staining, CTL assays, quantitation T-regulatory cells. Clinical growth was brain MRI scans every 2 months, primary clinical endpoint 2-year survival. Results: All well tolerated, only mild side effects attributable vaccination imiquimod adjuvant. Increased levels CD8+ T cells reactive against antigens, (e.g., gp100, TRP-2, her-2, survivin, CMV antigens), detected patients. Median PFS OS have not been reached this trial. To date, 6 13 progressed, those died. The median date is 18.1 mos. 33.8 This compares favorably controls from published literature, 6.9 mos 14.6 Conclusions: demonstrates clinical/immunologic an vaccine glioblastoma. adjunctive use appears non-toxic, deserves further study. demonstrate active immunotherapy strategy can generate antigen-specific No significant financial relationships disclose.